Mike Tyson’s cannabis brand, Tyson 2.0, has become the latest North American company to target European expansion following Germany’s landmark legislative reform.
According to Benzinga, which first reported the story, Tyson 2.0 has signed a new partnership with PHCANN to exclusively cultivate, manufacture and distribute its products in Germany and the UK.
PHCANN International, one of Europe’s leading cannabis production and distribution companies, said last November following the appointment of its new CEO said its aim for the ‘upcoming period’ was to make ‘premium medical cannabis products even more accessible to any group of people’.
Its new tie-up is set to make good on this promise, stating that it formed part of a pivotal moment in the progress of Europe’s cannabis industry.
“We embrace this opportunity as many countries look toward regulatory changes. To partner with the TYSON 2.0 brand and join forces as well-respected industry leaders puts us in a position where we can lead the charge in pushing industry boundaries,” PHCANN International’s CEO Sasho Stefanoski said.
Adam Wilkes, CEO of Tyson 2.0’s parent company Carma HoldCo, added: “With the Tyson 2.0 brand, we are excited to partner with PHCANN because of its track record of pushing the boundaries in European and other international markets and operating at a level above the current standard. By joining forces, we can deliver transformative experiences to medical cannabis consumers in Germany and the UK while leveraging our cultural influence to make a meaningful impact on the market.”
It comes just days after Canadian Stock Exchange-listed Curaleaf, the largest grower and distributor of cannabis in the world, was reported to be eyeing a secondary listing in Germany.
According to reports, the recent passage of Germany’s CanG act has encouraged the cannabis giant to increase its presence in the European market via a listing on the Frankfurt Stock Exchange.
Last month, Business of Cannabis reported that Curaleaf had acquired Canadian cannabis company Northern Green Canada (NGC), one of the few producers in the country to hold an EU-GMP licence.
The move put Curaleaf in a far stronger position to export its products into Europe, particularly Germany’s medical cannabis market.
